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Background: This retrospective, single centre study was conducted to investigate the efficacy of fibrinogen
concentrate (FBNc) in decreasing blood requirements and reaching optimal fibrinogen level, in non-trauma, massively
transfused, bleeding patients with coagulopathy.
Methods: Over a 3-years period, all patients for whom a massive transfusion protocol was activated and had received ≥4
units of allogeneic blood components within a ≤4 h period, were included. Patients were classified according to whether
they received FBNc or achieved an optimal fibrinogen level of ≥2 g/L within 24 h after FBNc administration.
Results: Seventy-one patients received 2 [2,4] g of FBNc (FBNc group) and 72 did not (comparator group). FBNc was
administered after transfusing 5 [5,9] blood component units, 3 [2,6] hours after massive transfusion protocol activation.
Linear regression analysis showed that SOFA (AOR 0.75 [95% CI:0.08-1.43]) and admission fibrinogen level (AOR −2.7
[95% CI:-4.68 – -0.78]), but not FBNc administration, were independently associated with total transfused units.
There was a significant inverse relation between both admission and target fibrinogen levels, and total transfused
components. Logistic regression showed a direct relationship between admission fibrinogen level and achieving a
target level ≥2 g/L (AOR 3.29 [95% CI;1.95-5.56]). No thromboembolic events associated with FBNc were observed.
Conclusions: In massively transfused, non-trauma patients with coagulopathy and refractory bleeding, late administration
of low FBNc dosage was not associated with decreased blood transfusion or increased post-infusion fibrinogen level. Given
that both fibrinogen upon admission and target fibrinogen levels were associated with decreased blood transfusion, earlier
administration and higher doses of FBNc could be needed.
Keywords: Anaemia, Bleeding, Clauss method, Fibrinogen concentrate, Goal directed therapy, Massive transfusion protocol,
Thromboelastometry, ROTEM, Thromboelastography, TEG, FIBTEM, TransfusionBackground
Fibrinogen is the most abundant coagulation factor and
the first one in reaching critical low levels during severe
bleeding [1]. In patients with major bleeding, require-
ments for fibrinogen are larger than for any other haemo-
static protein [2]. Trauma and surgical bleeding patients
often present low levels of fibrinogen, and bleeding* Correspondence: srlealnoval@gmail.com
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article, unless otherwise stated.volume and hypofibrinogenemia appears to be associ-
ated with poor clinical outcome [1,3].
Replacement of acquired fibrinogen deficiency with
fibrinogen concentrate (FBNc) in patients with massive
haemorrhage seems to be more efficacious than plasma
in decreasing bleeding and transfusion rate [3]. Add-
itionally, the administration FBNc (20 mg/mL) offers
the theoretical benefits of infusing up to tenfold more
fibrinogen than fresh frozen plasma (FFP, 2–3 mg/mL),
in less volume and time. However, plasma contains alltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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its administration [1,4].
Supplementation with fibrinogen may be more effective
when used as a part of an early goal-directed therapy in
bleeding patients [5,6]. In these cases, viscoelastic test-
guided, early FBNc administration, avoiding unacceptable
standard laboratory test delays, has been shown to decrease
blood transfusion requirements [5-9] and to be cost -
effective [8,9].
Guidelines recommend plasma and/or FBNc adminis-
tration for acquired hypofibrinogenemia in patients with
severe bleeding and coagulopathy following surgery or
major trauma [10-13]. However, its use as adjuvant ther-
apy for patients requiring massive transfusion is not yet
a widely approved indication for FBNc [7], even though
many countries have licensed FBNc for treatment of
congenital and acquired fibrinogen deficiencies [14].
The efficacy of FBNc in decreasing blood requirements
in non-trauma clinical settings have been addressed in
few studies, most of them without a comparator group
[3]. Therefore, the evidence regarding indications, dos-
ing, timing, efficacy and safety of FBNc administration
in massively transfused non-trauma patients is scarce
[15]. Nevertheless, the European guidelines for the man-
agement of severe perioperative bleeding recommends
treatment with FBNc if significant bleeding is accompanied
by at least suspected low fibrinogen concentrations or func-
tion (1C) [10]. A fibrinogen concentration <1.5–2.0 g/L orFigure 1 Current massive transfusion protocol (MTP) for managemen
Virgen del Rocio, Seville (Spain).thromboelastrometry (ROTEM) / thromboelastrogra-
phy (TEG) signs of functional fibrinogen deficiency should
be triggers for fibrinogen substitution (1C) [10].
Three years ago, our institution approved the use of
FBNc, as a part of the massive transfusion protocol
(MTP), after administration of the first transfusion pack-
age, in bleeding patients with fibrinogen levels of less
than 1.5 g/L (Clauss method) (Figure 1). This retrospect-
ive, single-centre study with a comparator group assessed
whether FBNc administration to massively transfused
non-trauma patients with on-going bleeding could attain
the target fibrinogen levels recommended by guidelines
and reduce transfusion requirements (primary endpoints).
Methods
Setting and study design
This is a retrospective, single-centre, cohort study of pa-
tients admitted to the teaching hospital “Virgen del Rocío”,
Seville, Spain, over a 3-years period (January 2011 through
December 2013). The study was approved by the Hospital
“Virgen del Rocío” Ethics Committee who waived the need
for obtaining patients’ written consent.
The hospital performs complex procedures including
cardiac, liver transplantation and gastrointestinal surger-
ies and has a transfusion guideline elaborated for the
Transfusion Committee available on its intranet page.
This guideline includes a massive transfusion protocol
(MTP), which is activated by the patient’s attendingt of patients with massive haemorrhage at University Hospital
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gency physician) (Figure 1). Blood components are indi-
cated with restrictive criteria and guided by patient’s signs
and symptoms, rather than merely by laboratory values.
Alternatives to blood transfusion, including the adminis-
tration of coagulation factors, are used according to the
recommendations of the “Spanish consensus statement
on alternatives to allogeneic blood transfusion: the
2013 update of the Seville Document” [12].
Massive bleeding was defined as the need for transfusion
of more than 4 blood component units within a 4-hour
period or bleeding leading to haemorrhagic shock, hyperlac-
tacidemia and vena cava oxygen-haemoglobin desaturation.
Fibrinogen concentrate (FBNc: Haemocomplettan®,
Riastap®; CSL Behring GmbH, Marburg, Germany) was
only considered if persisting diffuse bleeding after the
first massive transfusion package (4 packed red blood
cell [PRBC] units, 2 fresh frozen plasma [FFP] units
and 1 platelet [PLT] pool; (Figure 1), and hypofibrino-
genemia was suspected or definitely detected by con-
ventional laboratory tests (<1.5 g/dL by Clauss method
or derived fibrinogen assay). Usually, 25–50 mg/kg of
FBNc was administered in order to reach fibrinogen
levels of 1.5 - 2.0 g/L, but never as a first-line therapy.
For the proposal of this study, all the patients who re-
ceived 4 or more units of blood components over a 4-hours
period during the peri-operative period or after admission to
the emergency room or ICU were initially included. Exclu-
sion criteria comprised patients who died within 24-hour
from haemorrhage onset, because of uncontrolled multipleFigure 2 Patients (N) included into a massive transfusion protocol. Co
or not (comparator group) fibrinogen concentrate (FBNc); (2) patients receiv
pair-matched by SOFA, age and diagnosis; and (3) patients achieving orfactors which led to early death could explain the primary
outcome (flow chart, Figure 2), and those on oral anticoagu-
lant therapy or with incomplete clinical records.
Groups and variables
For each patient, a set of demographic and clinical vari-
ables including age, gender, severity of illness at the onset
of bleeding (as assessed by SOFA: sepsis organ failure as-
sessment), admitting diagnosis, length of hospital stay,
complications, total number of transfused units (PRBC,
FFP and PLT pools), and crude in-hospital mortality were
retrospectively gathered. Multiple laboratory data includ-
ing clotting tests and fibrinogen levels were also recorded.
Both the total number of transfused units and laboratory
tests were documented from 12 hours before to 12 hours
after FBNc administration.
For clarity in data presentation, four diagnostic groups
were considered: cardiac surgery, liver transplantation,
gastrointestinal bleeding, and mixed group. Haemorrhagic
episodes occurring at the operating room or ICU vs.
general medical or surgical wards or emergency depart-
ment were also differentiated.
The efficacy of FBNc administration was assessed by
its ability at decreasing blood transfusion, as well as at
attaining a target fibrinogen level of at least 2 g/L (Pri-
mary endpoints).
For the first primary endpoint, patients were classified
according to whether or not they had received FBNc.
Subjects with massive bleeding who did not receive
FBNc formed the comparator group. Patients treatedmparisons were performed between: (1) patients receiving (FBNc group)
ing (FBNc group) or not (comparator group) FBNc and successfully
not a fibrinogen level ≥2 g/l
Table 1 Characteristics of both cohorts of patients,
receiving (FBNc group) or not (comparator group) FBNc
Variables FBNc N = 71 Comparator
N = 72
P value
Age (years) 57 [44, 66] 63 [53, 72] 0.02
SOFA 7 [4, 10] 5 [3, 8] 0.03
Gender (males) 46 (65) 55 (76) NS
Haemorrhage occurring
outside the OR or ICU
25 (35.2) 24 (33.3) NS
Diagnoses
Cardiac Surgery 37 (51.4) 35 (49.3) NS
Liver Transplantation 11 (15.3) 11 (15.5)
Gastrointestinal Bleeding 16 (22.2) 15 (21.1)
Other 8 (11.1) 10 (14.1)
Variables at beginning of
the bleeding
pH 7.30 [7.29, 7.32] 7.31 [7.26, 7.3] NS
Base excess (mEq/L) −4.3 [−7.3, −3.0] −4.0 [−6.2, 0.3] 0.04
Creatinine (mg/dl) 0.9 [0.7, 1.3] 0.9 [0.7, 1.6] NS
Leukocytes (x 109/L) 7.4 [4.7, 12.9] 10.3 [8.1,14.6] 0.04
Platelets (x 109/L) 93 [49, 150] 100 [63, 144] NS
Haemoglobin (g/L) 85.0 [71.5, 103.0] 70.0 [64.0, 75.0] 0.001
Prothrombin time (s) 19.2 [14.1, 31.6] 16.7 [14.7, 20.3] NS
Thromboplastin time (s) 46.1 [34.1, 97.3] 43.5 [34.0, 55.5] NS
Fibrinogen (g/L) 1.3 [0.9, 2.2] 2.0 [1.4, 3.1] 0.001
INR 1.7 [1.2, 2.8] 1.4 [1.2, 1.7] 0.01
Outcome variables
In-hospital mortality 29 (40.8) 20 (27.8) NS
Length of hospital
stay (days)*
14 [7, 30] 23 [17, 33] 0.01
PRBC (units) 9 [5, 16] 6 [4,10] 0.001
FFP (units) 2 [0, 6] 3 [0, 6] NS
Platelet (pools) 2 [1, 3] 1 [0, 2] 0.001
Total transfusion (units) 15 [8, 25] 10 [6, 18] 0.02
FBNc: Fibrinogen concentrate; SOFA: Sepsis organ failure assessment; OR:
Operating room; ICU: Intensive care unit; INR: International normalized ratio;
PRBC: Packed red blood cell; FFP: Fresh frozen plasma; Quantitative variables
are expressed as a median [interquartile range]. Qualitative variables are
expressed as a number (percentage).
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The primary endpoint was the total number of allo-
geneic blood components administered since the MTP
activation.
Additionally, given that severity of illness, diagnostic
group and age may remain as strong confounders for de-
termining the primary end point despite multivariate
analysis, data were re-analysed after performing a match-
ing process (Figure 2, bullet 2). Each patient from the
FBNc group was pair-matched with other one from the
comparator group, upon fulfilment the matching criteria
of belong to the same diagnostic group, and present with
the same SOFA score (±2) and age (±5 years).
Afterwards, for the second primary endpoint, we in-
vestigated those factors associated with reaching a target
fibrinogen level of at least 2.0 g/L within a time period
of 24 hours, regardless of whether they received or not
FBNc. (Figure 2, bullet 3).
Secondary endpoints included the number of units of
each individual blood component given (PRBC, FFP, and
PLT pool), the length of hospital stay (days), and the
rates of thromboembolic adverse events and crude in-
hospital mortality. Medical records were carefully reviewed
in order to detect any myocardial infarction, cerebral
stroke, pulmonary thromboembolism and/or deep venous
thrombosis occurring from MTP activation to hospital
discharge.
Statistical analysis
To detect a reduction of transfusion requirements of
at least 2 ± 2 units after FBNc administration, with an
80% power (β-error) and a 95% confidence interval (α-error)
for the nonparametric Wilcoxon rank sum test, data from at
least 60 patients per arm (comparator and FBNc) would be
needed.
Because most variables were non-normally distributed,
data are reported as median (interquartile range [IQR]) and
percentages. For continuous variables, comparisons between
groups were performed with the nonparametric Kruskall-
Wallis and Mann–Whitney tests, whereas Pearson’s chi
squared test was used for the comparison of proportions.
Continuous variables at different time periods (before and
after FBNc administration, within-group comparisons) were
compared with the nonparametric Wilcoxon rank sum test.
A general regression linear model (ANOVA), which
provides both a regression and variance analyses for a
dependent continuous variable, was developed for inves-
tigating variables independently associated with overall
transfusion requirements. Factors associated with achiev-
ing fibrinogen level ≥2 g/L, within a 24-hours period after
MTP activation, were investigated using a step forward
logistic regression analysis.
All statistical analyses were performed using a com-
puter software package with license (SPSS 18, SPSS, Inc.,Chicago, IL), and a p value of less than 0.05 was consid-
ered significant.Results
Between 2011 and 2013 a total of 143 patients (60 [48,
69]) years old, SOFA 6 [4,9], 76.6 % male) were treated
for massive haemorrhage in our centre (72 received ex-
clusively blood components, and 71 received blood com-
ponents plus FBNc). Patients’ demographics and clinical
characteristics are summarized in Table 1.
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first package of blood components within 40 minutes
from the activation of MTP. In contrast, the average
time for administration of FBNc was longer and variable
(3 [2,6] hours), because our MTP dictates that FBNc is
to be administered always after transfusing the first
massive transfusion package (Figure 1).
There was an inverse and independent correlation be-
tween transfusion requirements and fibrinogen levels
upon admission, as well as between transfusion require-
ments and maximal fibrinogen levels within 24-hours
after activating MTP (Figure 3). An increase by 3 units
of blood components transfused per each g/l decrease in
fibrinogen upon admission was observed.
First primary endpoint: total number of transfused units
Patients from the FBNc group (N= 71) received 2 [2,4] g of
FBNc. After administering FBNc, fibrinogen levels increased
from 1.3 [0.9, 2.3] g/L to 1.8 [1.2, 2.3] g/L (p = 0.13), and
both bleeding (only reliably measured for 33 patients) and
blood transfusion volumes were significantly reduced
(Table 2).
Subjects included in FBNc group were compared with
those from the comparator group (N = 72). As depicted in
Table 1, patients from the FBNc group were significantly
sicker (higher SOFA), presented a more altered haemosta-
sis, were more frequently transfused, and had a higher
mortality. However, in the multivariate regression analysis,
only high SOFA score and low fibrinogen levels upon ad-
mission showed an independent association with total
number of transfused units (primary endpoint) (Table 3).Figure 3 Relationship between the global number of transfused units
levels within 24-hours after activating massive transfusion protocol (bAs severity of illness (as assessed by SOFA), age and diag-
noses could remain as strong confounder variables, data
were re-analysed after performing a pair-matching. Seventy-
six patients (38 in each group) were successfully matched,
and no differences with respect to number of transfused
units or mortality between groups were observed (Table 4).
Second primary endpoint: achievement of fibrinogen
levels ≥2 g/L, within a 24-hours period after activating
the MTP (N = 143 patients)
Patients who maintained a fibrinogen levels of less than
2 g/l (N = 64), presented a more altered haemostasis, were
more frequently transfused, and had a higher mortality
(NS) than those who not (N = 77). Fibrinogen levels before
of activation of MTP were also significantly lower, and
they received higher doses of FBNc (Table 5). After adjust-
ing, only fibrinogen level on admission was directly associ-
ated with achieving an optimal fibrinogen level ≥2 g/L
(AOR 3.29 [CI 1.95 - 5.56]; p < 0.0001). However, neither
the administered doses of FBNc nor the total number of
transfused units influenced the achievement of optimal
fibrinogen levels.
Secondary endpoints
Factors associated with increased mortality were also
investigated by step forward logistic regression analysis
(Table 6). SOFA upon admission, low pH and bleeding
occurring outside the operating room or ICU were in-
dependently associated with increased mortality. No
thromboembolic adverse events associated with FBNc
administration were observed.and fibrinogen levels upon admission (baseline) (a) and highest
).
Table 2 Laboratory values and transfused units before
and after FBNc administration
Variables Pre-FBNc Post-FBNc P value
pH 7.30 [7.28, 7.32] 7.32 [7.26, 7.36] 0.03
Base excess (mEq/L) −4.3 [−8.0, −3.0] −4.0 [−7.0, −2.0] NS
Creatinine (mg/dl) 0.9 [0.7, 1.2] 0.9 [0.7, 1.3] NS
Platelets (x 109/L) 93 [48, 156] 80 [59, 114] NS
Haemoglobin (g/L) 85.0 [71.0, 106.0] 90.0 [76.0, 100.0] NS
Prothrombin time (s) 19.2 [14.0, 31.9] 18.0 [15.4, 24.1] NS
Thromboplastin time (s) 46.1 [33.7, 98.6] 41.3 [32.6, 58.2] 0.02
Fibrinogen (g/L) 1.3 [0.9, 2.3] 1.8 [1.2, 2.3] NS
INR 1.7 [1.2, 2.8] 1.6 [1.3, 2.0] NS
Outcome variables
PRBC (units) 4 [3, 6] 2 [1, 3] 0.00
FFP (units) 1 [0, 2] 0 [0, 2] NS
Platelet (pools) 1 [0, 2] 0 [0, 1] 0.00
Total (units) 6 [5, 9] 3 [1, 6] 0.00
Bleeding (mL)* 1000 [670, 2000] 450 [242, 700] 0.00
Only patients receiving FBNc (N = 71) are considered (within-group
comparison). *Bleeding was measured accurately only in 33 patients.
(See caption for Table 1 for details).
Table 4 Matching, baseline and outcome variables for
patients receiving (FBNc group) or not (comparator
group) FBNc
Variables FBNc N = 38 Control
N = 38
P value
Age (years) 62 [55, 68] 62 [57, 73] NS
SOFA 6 [4, 8] 5.5 [4, 8] NS
Gender (males) 26 (68.4) 31 (81.5) NS
Haemorrhage occurring
outside the OR or ICU
10 (26.3) 10 (26.3) NS
Diagnoses
Cardiac surgery 21 (55.3) 21 (55.3)
Liver transplantation 7 (18.4) 7 (18.4)
Gastrointestinal bleeding 10 (26.6) 10 (26.6) NS
Variables at beginning of
bleeding
pH 7.30 [7.28, 7.33] 7.31 [7.26, 7.37] NS
Base excess (mEq/L) −4.7 [−8.0, −3.0] −4.0 [−6.0, 0.4] NS
Creatinine (mg/dL) 0.8 [0.7, 1.3] 0.9 [0.7, 1.4] NS
Leucocytes (x 109/L) 7.1 [4.7,11.7] 9.7 [7.3, 15.0] 0.04
Platelets (x 109/L) 112 [72, 173] 98 [63, 144] NS
Haemoglobin (g/L) 84.5 [72.0, 108.0] 70.0 [64.0, 75.0] 0.00
Prothrombin time (s) 18.0 [13.0, 28.0] 18.0 [14.0, 21.0] NS
Thromboplastin time (s) 43.5 [32.4, 63.8] 47.7 [36.2, 59.2] NS
Fibrinogen (g/L) 1.7 [0.9, 2.3] 2.0 [1.5, 3.3] 0.04
INR 1.6 [1.2, 2.5] 1.5 [1.2, 1.8] NS
Outcome variables
In-hospital mortality 13 (34.2) 10 (26.3) NS
Length of hospital
stay (days)*
15 [7, 32] 22 [14, 29] NS
PRBC (units) 8 [5, 12] 6 [5, 12] NS
FFP (units) 2 [0, 5] 3 [0, 5] NS
Platelet (pools) 1 [0, 2] 2 [1, 3] NS
Total transfusion (units) 11 [6, 20] 10 [6, 16] NS
Only 76 patients were successfully pair-matched (38 pairs). (See caption for
Table 1 for details).
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Fibrinogen concentrate administration has been found ef-
ficacious at reducing transfusion requirements in trauma
and surgical bleeding patients, when used as a first line
therapy within a goal-directed coagulation management al-
gorithm, based on point-of-care testing [8,9,14]. However,
less is known regarding the utility of FBNc for controlling
on-going haemorrhage and coagulopathy in non-trauma
patients in whom a MTP has failed in improving the
haemostasis and halting blood loss.
When assessed by adjusted analyses, our data showed
that fibrinogen level upon admission was the only vari-
able independently associated with both the global num-
ber of transfused units and the achievement of a target
fibrinogen level of at least 2 g/L. Low and late dosage
of FBNc (roughly 25 mg/kg) was found insufficient for
attaining any of these endpoints. In agreement with
published evidence on its high safety profile, even if
administered at high doses (100 mg/kg) [1,6,8], no FBNc-
associated thromboembolic event was observed.
As in other non-randomised studies [1,3], we observed a
non-adjusted significant decrement of the total number ofTable 3 Multiple linear regression analysis (ANOVA) for
variables involved in total transfusion
Variables B coefficient 95% CI p value
SOFA upon admission 0.75 0.08 – 1.43 0.02
Fibrinogen level upon
admission
- 2.7 - 4.68 – - 0.78 0.01
CI: Confidence interval; SOFA: Sepsis organ failure assessment.transfused units after administering FBNc (N = 71 pa-
tients, within-group comparison) (Table 2). However, after
adjusting, only the severity of illness, as assessed by SOFA,
and low fibrinogen levels on admission, but not FBNc ad-
ministration, were independently associated with blood
component requirements (Table 3). Additionally, no dif-
ferences in overall transfused units were observed after
performing a paired-matched between-group comparison
(Table 4).
Data on the use of massive transfusion protocols (MTP),
outside of the trauma setting, are scant. The activation of
MTP allows a faster and uniform issuing of blood prod-
ucts, though clinical outcome remains poor [16,17], and
Table 5 Patients’ characteristics according to the
achievement of an optimal fibrinogen level ≥2 g/L (maximum
fibrinogen level within 24 hours after the onset of bleeding)
Variables Fibrinogen ≥ 2 g/l
N= 77
Fibrinogen < 2 g/l
N=64
P value
Age (years) 61 [48, 70] 59 [44, 67] NS
SOFA 5 [3, 8] 6 [4, 9] NS
Gender (males) 54 (54.5) 45 (45.5) NS
FBN administration 0 [0, 2] 2 [0, 3] 0.00
Haemorrhage occurring
outside the OR or ICU
22 (28.5) 26 (40.6) NS
Diagnoses
Cardiac surgery 43 (55.8) 28 (43.8)
Liver transplantation 12 (15.6) 10 (15.6)
Gastrointestinal
bleeding
13 (16.9) 18 (28.1) NS
Other 9 (11.7) 8 (12,7)
Variables at beginning
of the bleeding
pH 7.3 [7.3, 7.4] 7.3 [7.2, 7.3] 0.04
Base excess (mEq/L) −3 [−7, −2] −6 [−9, −4] NS
Creatinine (mg/dl) 0.9 [0.7, 1.6] 0.9 [0.7, 1.3] NS
Leukocytes (x 109/L) 9.9 [7.0, 14.5] 7.9 [4.7, 12.9] 0.02
Platelets (x 109/L) 109 [65, 164] 88 [50, 126] 0.04
Haemoglobin (g/L) 74.0 [66.7, 85.0] 76.0 [65.0, 87.0] NS
Prothrombin time (s) 16 [14, 21] 19 [16, 27] 0.02
Thromboplastin
Time (s)
38 [31, 55] 58 [33, 74] 0.03
Fibrinogen (g/L) 2.1 [1.5, 3.2] 1.3 [1.0, 1.7] 0.00




18 [10, 32] 18 [8, 26] NS
PRBC (units) 7 [5, 9] 12 [6, 18] 0.00
FFP (units) 3 [0, 5] 4 [0, 8] NS
Platelet (pools) 1 [0, 2] 2 [1, 4] 0.00
Total transfusion (units) 10 [6, 16] 16 [7, 30] 0.00
Mortality 22 (28.6) 27 (42.2) NS
Table 6 Logistic regression analysis for variables involved
in hospital mortality
Variables Wald AOR [CI 95%] p value
SOFA on admission 11.4 1.31 [1.12 - 1.53] 0.01
pH at the onset of bleeding 10.5 0.00 [0.00 - 0.0001] 0.01
Bleeding occurring outside
the OR or ICU
6.9 3.73 [1.39 - 9.97] 0.002
CI: Confidence interval; ICU: Intensive care unit; OR: Operating room; SOFA:
Sepsis organ failure assessment.
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become widespread [2], though the European guidelines
for management of severe perioperative bleeding [10] do
not provide precise recommendations either for plasma
transfusion or for any specific plasma: RBC transfusion ra-
tio. In contrast, these guidelines definitely recommend the
use of predefined algorithms based on POC coagulations
monitoring assays to guide haemostatic interventions
aimed at improving outcome in elective surgery (1C) [10].
Regarding FBNc, with the exception of US guidelines,
published guidelines suggest or recommend its adminis-
tration in bleeding patients with either fibrinogen levels
below 1.5 - 2.0 g/L or FIBTEM ROTEM evidence of
functional fibrinogen deficiency [10-13,18-20], despite
this is not an approved indication for FBNc in all coun-
tries [14]. Therefore, the risk to benefit balance of using
FBNc as part of the MTP should be discussed at any
institution.
We observed that both low fibrinogen levels on admis-
sion and maximum fibrinogen level within a 24-hours
period after MTP activation were inversely and independ-
ently correlated with the number of transfused units
(Figure 3): blood component transfusion increased by
almost 3 units per each g/L decrease in admission fibrino-
gen level (Table 3). This is in agreement with the signifi-
cant though weak-to-moderate correlation (R = −0.40)
between pre- and postoperative fibrinogen levels and
postoperative blood loss in cardiac surgery, found in a
recent meta-analysis [21]. However, FBNc administra-
tion did not reduce the use the allogeneic blood products
in our patients (Table 3). More important, administration
of low doses of FBNc was not associated with reaching an
optimal fibrinogen level at least of 2 g/L. Several factors
may have accounted for the apparent lack of efficacy of
FBNc in this scenario.
First, these were bleeding patients (roughly one half
undergoing cardiovascular or hepatic surgery) who had
already received at least one massive transfusion package
before administering FNBc. Our patient management
protocol is opposed to that for patients included into a
goal-directed therapy algorithm. For the later, two recent
meta-analysis of 6 and 12 RCTs, respectively, demon-
strated that administration of variable, goal-directed
doses of FBNc effectively decreased transfusion require-
ments (6,15).
Second, the administered FBNc doses were at the lower
range of guidelines’ recommendations [10]. We adminis-
tered 2 [1,6] g of FBNc reaching a post infusion fibrinogen
level of 1.8 g/L. However, in 25% of patients, fibrinogen
remained lower than 1.2 g/L within 12-hours following
administration (Table 2). Moreover, for the whole sample
(N = 141), only 53.8 % attained fibrinogen levels ≥2 g/L,
despite massive transfusion, with or without the additional
FBNc.
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duce bleeding [6,8,9] and improve coagulopathy [22,23].
Therefore, it is possible that FBNc doses were too low,
resulting in inappropriate fibrinogen levels for improving
haemostasis.
Third, independently of the threshold and target levels
for FBNc administration, timing is also an important
issue, which is not accounted for in current guidelines.
In patients with massive haemorrhage, waiting for stand-
ard laboratory fibrinogen assessment invariably resulted
in late FBNc administration [24]. Even if FIBTEM ROTEM
is used, a minimum running time will be needed (10–15
minutes), albeit significantly shorter than that for conven-
tional laboratory [24].
We administered FBNc belatedly, when patients had
already received 6 [5,9] units of blood components and
had severe coagulopathy. Although speculative, it is con-
ceivable that FBNc efficacy was sub-optimal because of
late coagulopathy affecting platelets, proenzymes, and
the fibrinolytic system [25]. Earlier administration of
coagulation factor concentrates might have resulted in
improved treatment of coagulopathy and avoided the
side effects of plasma administration [24].
Lastly, a selection bias could have contributed to the
apparent lack of efficacy of FBNc administration ob-
served in our series. As depicted in Figure 1, clinicians
were free for administering plasma, FBNc or both. In
fact, FBNc was prescribed after transfusion of blood
components had failed to correct coagulopathy and
bleeding. Therefore, FBNc administration might actu-
ally be a surrogate marker of severity of illness.
Some limitations of our study should be acknowledged.
First, its retrospective, uncontrolled nature does not allow
an adequate estimation of the impact of FBNc therapy on
transfusion requirements. However, adjusted analyses and
matched comparison tried to overcome this bias. Second,
blood transfusion is a surrogate marker of blood loss,
and therefore changes in blood losses should have reflected
better the efficacy of FBNc. Unfortunately, it was difficult
to accurately measure the amount of blood loss. Third,
patients who died within 24-hours from the onset of
massive bleeding were excluded from the study. Lastly,
we reviewed the FBNc efficacy at treating massive
haemorrhage in non-trauma patients with heteroge-
neous diagnoses.
Despite the abovementioned limitations, our study
has also important strengths. This is one of the few
studies dealing with the use of FBNc, as a haemostatic
intervention, in patients with severe perioperative bleeding
managed with a MTP, and reporting on a relatively
large sample of patients. Moreover, unlike most pub-
lished studies, we performed multivariate analyses
and used a comparator group to document FBNc
efficacy.Conclusion
Our results suggest that the late administration of low
doses of FBNc is not useful in massively transfused pa-
tients with severe coagulopathy. However, independent
associations between severity of illness and low levels of
fibrinogen upon admission with transfusion requirements
were found. Therefore, it is conceivable that earlier ad-
ministration of higher doses, based on a goal-directed,
POC-guided algorithm, would improve FBNc effectiveness
in this clinical setting. We recognize that our results nei-
ther suggest nor support the inefficacy of FBNc, but rather
the probable inefficacy of its inappropriate use. Prospect-
ive studies on the role of FBNc administration to non-
trauma patients with severe bleeding are urgently needed.
Key messages
– The late administration of low doses of fibrinogen
concentrate is not useful in massively transfused
patients with severe coagulopathy.
– Low fibrinogen upon admission and maximum
fibrinogen level were inversely associated with
transfusion rate. Requirements of blood component
transfusion increased by 3 units per each g/L
decrease in admission fibrinogen levels.
– Our data also suggest that both earlier administration
and higher doses could improve FBNc effectiveness in
massively transfused patients with coagulopathy.
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